IL194232A - Methods for cell expansion, cells and conditioned media produced thereby and medicaments comprising same - Google Patents
Methods for cell expansion, cells and conditioned media produced thereby and medicaments comprising sameInfo
- Publication number
- IL194232A IL194232A IL194232A IL19423208A IL194232A IL 194232 A IL194232 A IL 194232A IL 194232 A IL194232 A IL 194232A IL 19423208 A IL19423208 A IL 19423208A IL 194232 A IL194232 A IL 194232A
- Authority
- IL
- Israel
- Prior art keywords
- cells
- adherent
- placenta
- stromal cells
- culture
- Prior art date
Links
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (18)
1. A method of expanding a population of adherent stromal cells, the method comprising: i. culturing adherent stromal cells obtained from placenta or adipose tissue under three-dimensional culturing conditions, which support cell expansion; and ii. harvesting the expanded adherent stromal cells from the three dimensional culture system.
2. A method of producing a conditioned culture medium comprising culturing adherent stromal cells obtained from a placenta or adipose tissue in three dimensional culture conditions which allow cell expansion thereby producing a conditioned medium, and collecting the conditioned medium thereby producing a conditioned culture medium comprising Fit- 3 ligand, IL-6, and SCF.
3. The method of claim 1, wherein the adherent stromal cells are obtained from a placenta.
4. A population of expanded adherent stromal cells generated according to the method of claim 1.
5. The population of expanded adherent stromal cells of claim 4, wherein the cells suppress an immune reaction.
6. A conditioned culture medium made according to the method of claim 2.
7. A pharmaceutical composition comprising the adherent stromal cells of claim 4 and a pharmaceutically acceptable carrier.
8. The method of claim 1 , wherein said three dimensional culture system comprises a three- dimensional (3D) bioreactor. 44 194232/03
9. The method of claim 1, wherein said culturing is effected for at least 3 days.
10. The method of claim 1, wherein the adherent stromal cells are cultured to at least 60 % confluence.
11. An isolated population of cells comprising adherent stromal cells of placenta or adipose tissue, wherein said adherent cells are grown in a three dimensional culture and are characterized by at least one of: (i) secretion of a higher level of at least one factor selected from the group consisting of SCF, IL-6, and Flt-3 than that secreted by adherent cells of placenta or adipose tissue grown in a 2D culture; (ii) expression of a higher level of at least one protein selected from the group consisting of H2A histone family (H2AF), Aldehyde dehydrogenase X (ALDH X), eukaryotic translation elongation factor 2 (EEEF2), reticulocalbin 3, EF-hand calcium binding domain (RCN2) and calponin 1 basic smooth muscle (CNN1) than that expressed by adherent cells of placenta or adipose tissue grown in a 2D culture; (iii) expression of a lower level of at least one protein selected from the group consisting of heterogeneous nuclear ribonucleoprotein HI (Hnrphl), CD44 antigen isoform 2 precursor, 3 phosphoadenosine 5 phosphosulfate synthase 2 isoform a (Papss2) and ribosomal protein L7a (rpL7a) than that expressed by adherent cells of placenta or adipose tissue grown in a 2D culture; and (iiii) a higher immunosuppressive activity than that of adherent cells of placenta or adipose tissue grown in a 2D culture.
12. The isolated population of cells of claim 11, wherein said immunosuppressive activity comprises reduction in T cell proliferation.
13. A pharmaceutical composition comprising the cells of claim 11 and a pharmaceutically acceptable carrier. 194232/03
14. Use of the adherent stromal cells of claim 4 for the manufacture of a medicament identified for treating a condition selected from the group consisting of stem cell deficiency, heart disease, Parkinson's disease, cancer, Alzheimer's disease, stroke, burns, loss of tissue, loss of blood, anemia, autoimmune disorders, diabetes, arthritis, Multiple Sclerosis, graft vs. host disease (GvHD), neurodegenerative disorders, autoimmune encephalomyelitis (EAE), systemic lupus erythematosus (SLE), rheumatoid arthritis, systemic sclerosis, Sjorgen's syndrome, multiple sclerosis (MS), Myasthenia Gravis (MG), Guillain- Barre Syndrome (GBS), Hashimoto's Thyroiditis (HT), Graves's Disease, Insulin dependent Diabetes Melitus (IDDM) and Inflammatory Bowel Disease.
15. The use of claim 14, wherein said diabetes is insulin dependent diabetes mellitus (IDDM).
16. The method, cells or use of claims 1, 11 or 14, wherein said adherent cells express one or more of CD73, CD90, CD29 or CD105.
17. The method, cells or use of claims 1, 11 or 14, wherein said adherent stromal cells do not express CD45, CD80, HLA-DR, CDl lb, CD14, CD19, CD34 or CD79.
18. The use of claim 14, wherein said adherent stromal cells are characterized by at least one of: (i) secretion of a higher level of at least one factor selected from the group consisting of SCF, IL-6, and Flt-3 than that secreted by adherent cells of placenta or adipose tissue grown in a 2D culture; (ii) expression of a higher level of at least one protein selected from the group consisting of H2A histone family (H2AF), Aldehyde dehydrogenase X (ALDH X), eukaryotic translation elongation factor 2 (EEEF2), reticulocalbin 3, EF-hand calcium binding domain (RCN2) and calponin 1 basic smooth muscle (CNN1) than that expressed by adherent cells of placenta or adipose tissue grown in a 2D culture; (iii) expression of a lower level of at least one protein selected from the group consisting of heterogeneous nuclear ribonucleoprotein HI (Hnrphl), CD44 antigen
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL194232A IL194232A (en) | 2006-03-23 | 2008-09-21 | Methods for cell expansion, cells and conditioned media produced thereby and medicaments comprising same |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78476906P | 2006-03-23 | 2006-03-23 | |
| US84708806P | 2006-09-26 | 2006-09-26 | |
| PCT/IL2007/000380 WO2007108003A2 (en) | 2006-03-23 | 2007-03-22 | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy |
| IL194232A IL194232A (en) | 2006-03-23 | 2008-09-21 | Methods for cell expansion, cells and conditioned media produced thereby and medicaments comprising same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL194232A0 IL194232A0 (en) | 2011-08-01 |
| IL194232A true IL194232A (en) | 2014-12-31 |
Family
ID=44671842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL194232A IL194232A (en) | 2006-03-23 | 2008-09-21 | Methods for cell expansion, cells and conditioned media produced thereby and medicaments comprising same |
Country Status (1)
| Country | Link |
|---|---|
| IL (1) | IL194232A (en) |
-
2008
- 2008-09-21 IL IL194232A patent/IL194232A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| IL194232A0 (en) | 2011-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009531059A5 (en) | ||
| HRP20160538T1 (en) | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy | |
| Shaw et al. | Clinical applications of prenatal and postnatal therapy using stem cells retrieved from amniotic fluid | |
| Qian et al. | Primary mesenchymal stem and progenitor cells from bone marrow lack expression of CD44 protein | |
| Rebelatto et al. | Dissimilar differentiation of mesenchymal stem cells from bone marrow, umbilical cord blood, and adipose tissue | |
| JP2011529706A5 (en) | ||
| JP2009508507A5 (en) | ||
| Wang et al. | CD14+ monocytes promote the immunosuppressive effect of human umbilical cord matrix stem cells | |
| CA2652148A1 (en) | Tolerogenic dendritic cells, method for their production and uses thereof | |
| JP2014508527A5 (en) | ||
| Li et al. | TNFAIP6 defines the MSC subpopulation with enhanced immune suppression activities | |
| Kramer et al. | Rheumatoid arthritis: targeting the proliferative fibroblasts | |
| Kim et al. | Paradoxical effects of human adipose tissue-derived mesenchymal stem cells on progression of experimental arthritis in SKG mice | |
| IL194232A (en) | Methods for cell expansion, cells and conditioned media produced thereby and medicaments comprising same | |
| KR20180009435A (en) | Methods for isolation adipose-derived stromal vascular fraction from fat tissues | |
| Jiang et al. | Adipose tissue‑derived stem cells modulate immune function in vivo and promote long‑term hematopoiesis in vitro using the aGVHD model | |
| Reddy et al. | Mesenchymal stem cells as immunomodulator therapies for immune-mediated systemic dermatoses | |
| Prakoeswa et al. | The potential of mesenchymal stem‐cell secretome for regeneration of intervertebral disc: a review article | |
| Christner | Biosynthesis of chondroitin sulfate proteoglycan by P388D1 macrophage-like cell line. | |
| Tyndall et al. | Mesenchymal stem cells for multiple sclerosis: can we find the answer? | |
| Zhang et al. | Foot fat pad: Characterization by mesenchymal stromal cells in rats | |
| Sadeghi et al. | The Effects of Deferoxamine on the Up regulation of Chemokine Receptor 2 in Bone Marrow Stromal Stem Cells | |
| François et al. | Mesenchymal Stromal Cells: An Emerging Cell-Based Pharmaceutical | |
| Szekeres-Bartho et al. | Mónica Cruz-Barrera1, Nathalia Flórez-Zapata1, 2, Nicolás Lemus-Diaz3, Carlos Medina1, Cristian-Camilo Galindo1, Lorena-Xiomara González-Acero1, Luz Correa1, Bernardo Camacho1, Jens Gruber3 and Gustavo Salguero1 | |
| Lisak et al. | Collagen Vascular diseases and the nervous system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed |